Tarsus Pharmaceuticals Inc (NAS:TARS)
$ 55 0.65 (1.2%) Market Cap: 2.10 Bil Enterprise Value: 1.83 Bil PE Ratio: 0 PB Ratio: 8.85 GF Score: 48/100

Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 04:00PM GMT
Dane Leone
Raymond James Financial, Inc. - Analyst

Great. Welcome, everyone, to the next session here at Raymond James 2021 Human Health Innovation Conference. My name is Dane. I'm one of the senior biotech analysts with Raymond James.

For this session, we're going to have a fireside chat with the CEO of Tarsus. Very happy to have you here, Bobby. It's going to be a great discussion, very well-timed for some really clinical -- important clinical data that you had this week.

But maybe for some of our audience members that are less familiar with the Tarsus story, you could just give us a brief intro on yourself and a little bit background in terms of Tarsus and then we can go into maybe some specific questions.

Bobby Azamian
Tarsus Pharmaceuticals, Inc. - Co-founder, President and CEO

That's great, Dane. Thank you for having us here at the Raymond James conference. It is a really dynamic and exciting time at Tarsus. We just have read out our first pivotal trial, the first-ever pivotal trial for Demodex blepharitis, so we will tell you all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot